Valeria Cáceres
YOU?
Author Swipe
View article: Academic Collaborative Groups in Latin America: Key for High-Quality Standards and Personal and Collective Growth
Academic Collaborative Groups in Latin America: Key for High-Quality Standards and Personal and Collective Growth Open
Latin America's cultural diversity, political instability, and socioeconomic inequality contribute to fragmented health systems, hindering high-quality care and health equity. Financial limitations in health care exacerbate these issues, a…
View article: Assessment of immune-related rheumatological adverse events in a monovalent oncology center in Argentina
Assessment of immune-related rheumatological adverse events in a monovalent oncology center in Argentina Open
Background Immune checkpoint inhibitors (ICIs) has changed the outcome of oncology patients. They are being used in an increasingly number of different cancer types. As a consequence, there is an enhance report of toxicity ICIs associated,…
View article: Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Open
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 …
View article: #67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826
#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826 Open
Introduction/Background In KEYNOTE-826 (NCT03635567), pembrolizumab (pembro) + chemotherapy (chemo) ± bevacizumab (bev) provided statistically significant and clinically meaningful overall survival (OS) and progression-free survival (PFS) …
View article: 58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer
58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer Open
Introduction/Background* Pembrolizumab has efficacy in previously treated, PD-L1-positive advanced cervical cancer. KEYNOTE-826 (NCT03635567) was a phase 3, randomised, double-blind trial of pembrolizumab or placebo added to chemotherapy ±…
View article: FLABRA, Frontline Approach for <i>BRCA</i> Testing in an Ovarian Cancer Population: A Latin America Epidemiologic Study
FLABRA, Frontline Approach for <i>BRCA</i> Testing in an Ovarian Cancer Population: A Latin America Epidemiologic Study Open
Aim: FLABRA evaluated the prevalence of BRCA mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients & methods: Patients with ovarian cancer from six Latin-American countries were …
View article: Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries
Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries Open
Women and other mammalian females are born with a finite supply of oocytes that determine their reproductive lifespan. During fetal development, individual oocytes are enclosed by a protective layer of granulosa cells to form primordial fo…